It’s been six months since the release of Asteria Pharmaceutical’s groundbreaking sleeping pill, and already, profits are soaring. With the original clinical trial outliers in hiding and on the run, George Sturgis has had free rein to disperse his revolutionary genome-inhibiting medication to the masses, with little regard for Ocula’s unconventional side effects. Meanwhile, in Langley, the Director of Central Intelligence has taken notice of Ocula’s success and is determined to take the drug off the streets—even if it means rebooting a dangerous project she swore she would eliminate for good. As the original outliers get pulled deeper into the Ocula conspiracy, they’ll soon discover that they’re not the only ones dreaming.